Global malaria prevention programs have saved 14 million lives since 2000

Since the year 2000, coordinated global malaria prevention efforts have saved 14 million lives and averted 2.3 billion cases of the disease — including 1 million deaths prevented in 2024 alone. Those figures come from the World Health Organization’s World Malaria Report 2025, published Dec. 4, 2025, the most comprehensive annual assessment of global malaria control. The milestone reflects 25 years of sustained investment in bed nets, vaccines, diagnostics, and treatment access, primarily across sub-Saharan Africa.

• In 2024 alone, more than 170 million malaria cases and 1 million deaths were averted globally — meaning the pace of lives saved is accelerating, not slowing, even as total cases ticked upward.
• 47 countries and one territory are now officially certified malaria-free by WHO, including three new certifications in 2025: Georgia, Suriname — the first country in the Amazonian region to eliminate malaria — and Timor-Leste.
• The number of countries reporting fewer than 1,000 malaria cases annually has grown from 13 in 2000 to 37 in 2024, a nearly threefold increase that reflects how far elimination has advanced across multiple regions.

The progress did not happen by accident. The WHO World Malaria Report 2025 credits the scale-up of four core malaria prevention interventions: insecticide-treated bed nets, indoor residual spraying, seasonal malaria chemoprevention — which reached 55 million children across 19 countries in 2025 — and two newly approved malaria vaccines now being rolled out through routine childhood immunization programs across Africa. Each tool targets a different point in the transmission chain, and their combined deployment is what produced a generational decline in mortality.

How malaria prevention tools transformed survival rates

The bed net is the most visible symbol of the malaria prevention campaign, but its evolution over the past decade is less well known. As recently as 2019, next-generation dual-insecticide nets — designed to combat growing insecticide resistance among mosquitoes — made up just 10% of nets shipped globally. By 2024, that figure had risen to 84%. The shift was driven by the New Nets Project, a partnership spearheaded by Unitaid and the Global Fund and supported by the Gates Foundation and the U.S. President’s Malaria Initiative, which accelerated testing, manufacturing, and rollout of the improved nets at scale.

The vaccine story is newer. WHO approved the world’s first malaria vaccine, RTS,S/AS01, in 2021, followed by a second — R21/Matrix-M — in 2023. As of October 2025, 24 countries had introduced one or both vaccines into routine childhood immunization schedules. A multisectoral partnership between manufacturers, WHO, UNICEF, and Gavi, the Vaccine Alliance, enabled the rollout and drove down the per-dose price to make scale-up financially viable. In 2024, 17 African countries were already administering malaria vaccines. By 2025, seven more had begun.

Seasonal malaria chemoprevention — giving antimalarial drugs preventively to young children during peak transmission months — has also scaled significantly. In 2024, an average of 54 million children across 19 African countries received chemoprevention, with Nigeria, which carries the highest malaria burden of any country in the world, accounting for more than half.

The honest picture of what malaria prevention has not yet achieved

The 14 million lives saved figure is real and significant. So is the harder context that surrounds it. In 2024, there were still 282 million malaria cases and 610,000 deaths globally — up from 273 million cases and 597,000 deaths in 2023. Three countries — Ethiopia, Madagascar, and Yemen — accounted for 58% of the case increase. A child still dies from malaria roughly every minute, and 75% of deaths in Africa occur in children under 5.

Two emerging threats could reverse decades of progress. Partial resistance to artemisinin derivatives — the backbone of malaria treatment since the failure of earlier drugs — has now been confirmed or suspected in at least 8 African countries. Drug resistance, if it spreads, could render the most effective treatments obsolete. Insecticide resistance among Anopheles mosquitoes compounds the problem, weakening the bed nets and sprays that have been the primary prevention tools for two decades.

Funding is the second threat. Global malaria funding in 2024 reached $3.9 billion — only 42% of the $9.3 billion target set by the WHO’s Global Technical Strategy. The United States has historically been the largest international contributor to malaria programs. Cuts to U.S. foreign assistance in 2025 created uncertainty that, according to the WHO report, directly threatened the continuation of bed net distribution campaigns and chemoprevention rollouts in the countries that need them most.

The WHO Director-General warned directly: increasing cases, drug resistance, and funding cuts all threaten to roll back the progress of the past two decades. The tools to eliminate malaria now exist. The question is whether the world will pay for them.

Progress against malaria is part of a broader pattern of improving global health outcomes. The global suicide rate has fallen nearly 40% since 1995, and U.K. cancer death rates have reached their lowest level on record — evidence that sustained, evidence-based intervention works. More good news in global health is being made every year — most of it going unreported.

If you want to keep up with the progress being made, subscribe to the Good News for Humankind newsletter. And if the weight of the world’s ongoing crises is affecting your ability to keep doing good work, the Antihero Project is a coaching program built for people like you.

This story was originally reported by the World Health Organization.